The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Self-citationA novel genetic system to detect protein–protein interactions
Fields, S., & Song, O.-K. (1989) · Nature · doi:10.1038/340245a0 · Cited by 6,114
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Self-citationVogelstein, B. (1992) · Cell · doi:10.1016/0092-8674(92)90421-8 · Cited by 1,862
Self-citationOncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
Self-citationPresence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Fakharzadeh, S. S., Trusko, S. P., & George, D. L. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07676.x · Cited by 704
Dalton, S., & Treisman, R. (1992) · Cell · doi:10.1016/0092-8674(92)90194-h · Cited by 672
Research works printed but not linked: 4
- Miller, C. W., Imai, Y., Aslo, A., Li, L. & Koefler, H. P. Proc. Am. Assoc. Cancer Res. 33, 386 (1992).
- Sturzbecher, H. W. et al. Oncogene 7, 1513–1523 (1992).
- Friedman, P. N., Chen, X., Bargonetti, J. & Prives, C. Proc. natn. Acad. Sci. U.S.A. (in the press).
- Poon, D. et al. Molec. cell. Biol. 11, 4809–4821 (1991). · doi:10.1128/mcb.11.10.4809
Cited by
Items 101–190 of 190
The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344
Novel Insights into Mesothelioma Biology and Implications for Therapy
Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.42 · Cited by 324
Degradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335
MDM2 suppresses p73 function without promoting p73 degradation
Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Oren, M., Chen, J., & Lu, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3257 · Cited by 334
Willis, A., Jung, E. J., Wakefield, T., & Chen, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207396 · Cited by 330
Barak, Y., Gottlieb, E., Juven-Gershon, T., & Oren, M. (1994) · Genes & Development · doi:10.1101/gad.8.15.1739 · Cited by 328
“Based on the localization of the p53-binding site to the most amino-terminal portion of MDM2 (Chen et al. 1993; Oliner et al. 1993), an internally initiated MDM2 protein beginning at the fiftieth in-frame codon is expected not to bind p53.”
BackgroundThe p53 tumor suppressor participates in multiple cell cycle checkpoints
Giono, L. E., & Manfredi, J. J. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20689 · Cited by 328
MDM2 interacts with MDMX through their RING finger domains
Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., & Ohtsubo, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00254-9 · Cited by 324
Woods, D. B., & Vousden, K. H. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5141 · Cited by 319
ΔNp73, A Dominant-Negative Inhibitor of Wild-type p53 and TAp73, Is Up-regulated in Human Tumors
Zaika, A. I., Slade, N., Erster, S. H., Sansome, C., Joseph, T. W., Pearl, M., Chalas, E., & Moll, U. M. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020179 · Cited by 318
Blockage by Adenovirus E4orf6 of Transcriptional Activation by the p53 Tumor Suppressor
Dobner, T., Horikoshi, N., Rubenwolf, S., & Shenk, T. (1996) · Science · doi:10.1126/science.272.5267.1470 · Cited by 311
Yin, Y., Stephen, C. W., Luciani, M. G., & Fåhraeus, R. (2002) · Nature Cell Biology · doi:10.1038/ncb801 · Cited by 306
Alternative splicing in cancer: implications for biology and therapy
Chen, J., & Weiss, W. A. (2015) · Oncogene · doi:10.1038/onc.2013.570 · Cited by 304
Mechanisms underlying hypoxia-induced neuronal apoptosis
Banasiak, K. J., Xia, Y., & Haddad, G. G. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00011-3 · Cited by 303
Allosteric activation of latent p53 tetramers
Hupp, T. R., & Lane, D. P. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00195-0 · Cited by 301
Shieh, S.-Y. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1815 · Cited by 300
Foundations in Cancer Research p53 and ATM: Cell Cycle, Cell Death, and Cancer
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60095-0 · Cited by 300
Dohn, M., Zhang, S., & Chen, X. (2001) · Oncogene · doi:10.1038/sj.onc.1204427 · Cited by 294
Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401753e · Cited by 290
Self-citationStabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein
Sharp, D. A., Kratowicz, S. A., Sank, M. J., & George, D. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.53.38189 · Cited by 286
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2
Stevenson, L. F., Sparks, A., Allende‐Vega, N., Xirodimas, D. P., Lane, D. P., & Saville, M. K. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601567 · Cited by 280
Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53.
Yew, P. R., Liu, X., & Berk, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.2.190 · Cited by 283
Unfoldomics of human diseases: linking protein intrinsic disorder with diseases
Uversky, V. N., Oldfield, C. J., Midic, U., Xie, H., Xue, B., Vucetic, S., Iakoucheva, L. M., Obradovic, Z., & Dunker, A. K. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-s1-s7 · Cited by 281
Carroll, P. E., Okuda, M., Horn, H. F., Biddinger, P., Stambrook, P. J., Gleich, L. L., Li, Y.-Q., Tarapore, P., & Fukasawa, K. (1999) · Oncogene · doi:10.1038/sj.onc.1202515 · Cited by 279
Transcriptional Repression of p53 Promoter by Hepatitis C Virus Core Protein
Ray, R. B., Steele, R., Meyer, K., & Ray, R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.17.10983 · Cited by 279
A functional p53-responsive intronic promoter is contained within the human mdm2 gene
Zauberman, A., Flusberg, D., Haupt, Y., Barak, Y., & Oren, M. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.14.2584 · Cited by 276
To die or not to die: how does p53 decide?
Slee, E. A., O'Connor, D. J., & Lu, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207516 · Cited by 278
Sigalas, I., Calvert, A. H., Anderson, J. J., Neal, D. E., & Lunec, J. (1996) · Nature Medicine · doi:10.1038/nm0896-912 · Cited by 268
Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex
Weber, J. D., Kuo, M.-L., Bothner, B., DiGiammarino, E. L., Kriwacki, R. W., Roussel, M. F., & Sherr, C. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2517-2528.2000 · Cited by 275
Repression of p53-mediated transcription by MDM2: a dual mechanism
Thut, C. J., Goodrich, J. A., & Tjian, R. (1997) · Genes & Development · doi:10.1101/gad.11.15.1974 · Cited by 272
Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.
Chen, C. Y., Oliner, J. D., Zhan, Q., Fornace, A. J., Vogelstein, B., & Kastan, M. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2684 · Cited by 271
Self-citationRoads to polyploidy: The megakaryocyte example
Ravid, K., Lu, J., Zimmet, J. M., & Jones, M. R. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10035 · Cited by 267
Sandberg, A. A., & Bridge, J. A. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00105-5 · Cited by 262
Bohuslav, J., Chen, L.-F., Kwon, H., Mu, Y., & Greene, W. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313509200 · Cited by 256
Terphenyl‐Based Helical Mimetics That Disrupt the p53/HDM2 Interaction
Yin, H., Lee, G., Park, H. S., Payne, G. A., Rodriguez, J. M., Sebti, S. M., & Hamilton, A. D. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462316 · Cited by 255
Truant, R., Antunovic, J., Greenblatt, J., Prives, C., & Cromlish, J. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.3.1851-1859.1995 · Cited by 255
Majumder, M., Ghosh, A. K., Steele, R., Ray, R., & Ray, R. B. (2001) · Journal of Virology · doi:10.1128/jvi.75.3.1401-1407.2001 · Cited by 255
MDM2 Is a Negative Regulator of p21 , Independent of p53
Zhang, Z., Wang, H., Li, M., Agrawal, S., Chen, X., & Zhang, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312264200 · Cited by 252
Midgley, C. A., Desterro, J. M., Saville, M. K., Howard, S., Sparks, A., Hay, R. T., & Lane, D. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203593 · Cited by 252
Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma
Crago, A. M., & Singer, S. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834796e6 · Cited by 252
Engelhard, K., Werner, C., Eberspächer, E., Bachl, M., Blobner, M., Hildt, E., Hutzler, P., & Kochs, E. (2003) · Anesthesia & Analgesia · doi:10.1097/00000539-200302000-00041 · Cited by 252
Molecular characterization of the hdm2-p53 interaction 1 1Edited by J. Karn
Böttger, A., Böttger, V., Garcia-Echeverria, C., Chène, P., Hochkeppel, H.-K., Sampson, W., Ang, K., Howard, S. F., Picksley, S. M., & Lane, D. P. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1078 · Cited by 252
Hu, M., Gu, L., Li, M., Jeffrey, P. D., Gu, W., & Shi, Y. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040027 · Cited by 251
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Carvajal, L. A., Neriah, D. B., Senecal, A., Benard, L., Thiruthuvanathan, V., Yatsenko, T., Narayanagari, S.-R., Wheat, J. C., Todorova, T. I., Mitchell, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao3003 · Cited by 249
Itahana, K., Mao, H., Jin, A., Itahana, Y., Clegg, H. V., Lindström, M. S., Bhat, K. P., Godfrey, V. L., Evan, G. I., & Zhang, Y. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.09.007 · Cited by 245
The Role of MDM2 Amplification and Overexpression in Tumorigenesis
Oliner, J. D., Saiki, A. Y., & Caenepeel, S. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026336 · Cited by 246
“This inhibitory function was shown to be conferred through the ability of MDM2 to conceal the p53 activation domain from the cellular transcription machinery (Oliner et al. 1993).”
BackgroundSelf-citationmdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation
Mendrysa, S. M., McElwee, M. K., Michalowski, J., O'Leary, K. A., Young, K. M., & Perry, M. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.462-473.2003 · Cited by 234
Lundgren, K., Montes de Oca Luna, R., McNeill, Y. B., Emerick, E. P., Spencer, B., Barfield, C. R., Lozano, G., Rosenberg, M. P., & Finlay, C. A. (1997) · Genes & Development · doi:10.1101/gad.11.6.714 · Cited by 235
Ubiquitination and Degradation of Mutant p53
Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223
Cyclin G Recruits PP2A to Dephosphorylate Mdm2
Okamoto, K., Li, H., Jensen, M. R., Zhang, T., Taya, Y., Thorgeirsson, S. S., & Prives, C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00504-x · Cited by 215
Mdm2 binds p73α without targeting degradation
Bálint, E., Bates, S., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1202781 · Cited by 212
MdmX Protects p53 from Mdm2-Mediated Degradation
Jackson, M. W., & Berberich, S. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.3.1001-1007.2000 · Cited by 211
“Later it was discovered that Mdm2 could bind to p53, repress p53-dependent transactivation of target genes (21, 24), and promote rapid degradation of p53 through the ubiquitin-proteosome pathway (10, 16).”
BackgroundStructural Aspects of the p53 Protein in Relation to Gene Evolution: A Second Look
Soussi, T., & May, P. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0425 · Cited by 208
The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression
Minsky, N., & Oren, M. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.10.016 · Cited by 204
Overholtzer, M., Rao, P. H., Favis, R., Lu, X.-Y., Elowitz, M. B., Barany, F., Ladanyi, M., Gorlick, R., & Levine, A. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934852100 · Cited by 193
Phan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173
Inactivation of the p53-homologue p73 by the mdm2-oncoprotein
Dobbelstein, M., Wienzek, S., König, C., & Roth, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202512 · Cited by 161
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer Cells
Jallepalli, P. V., Lengauer, C., Vogelstein, B., & Bunz, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213159200 · Cited by 154
Self-citationCanon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0710 · Cited by 152
Self-citationPhosphorylation of Serine 18 Regulates Distinct p53 Functions in Mice
Sluss, H. K., Armata, H., Gallant, J., & Jones, S. N. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.3.976-984.2004 · Cited by 152
“The Mdm2 oncoprotein binds to the amino-terminal portion of the p53 protein (11, 48 ), induces p53 monoubiquitination and nuclear export (35, 39), and targets p53 for proteosomal degradation (23, 34).”
BackgroundBrown, D. R., Thomas, C. A., & Palit Deb, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.9.2513 · Cited by 148
Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M. E., Janzer, R. C., Merlo, A., & Van Meir, E. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203700 · Cited by 146
Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1
Inoue, K., Roussel, M. F., & Sherr, C. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3993 · Cited by 144
Hypophosphorylation of Mdm2 Augments p53 Stability
Blattner, C., Hay, T., Meek, D. W., & Lane, D. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.17.6170-6182.2002 · Cited by 144
(2002) · PubMed · Cited by 143
Regulation of p53: a collaboration between Mdm2 and MdmX
Pei, D., Zhang, Y., & Zheng, J. (2012) · Oncotarget · doi:10.18632/oncotarget.443 · Cited by 140
Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance
Kulikov, R., Boehme, K. A., & Blattner, C. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.16.7170-7180.2005 · Cited by 132
Zhuang, C., Miao, Z., Zhu, L., Dong, G., Guo, Z., Wang, S., Zhang, Y., Wu, Y., Yao, J., Sheng, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300969t · Cited by 131
Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer
Rew, Y., & Sun, D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500627s · Cited by 125
Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23
MacPherson, D., Kim, J., Kim, T., Rhee, B. K., van Oostrom, C. T., DiTullio, R. A., Venere, M., Halazonetis, T. D., Bronson, R., de Vries, A., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600363 · Cited by 124
“MDM2 also inhibits p53 by binding to the transactivation domain of p53 (Oliner et al, 1993).”
BackgroundRegulation of MDMX nuclear import and degradation by Chk2 and 14-3-3
LeBron, C., Chen, L., Gilkes, D. M., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601032 · Cited by 122
Wild-Type Human p53 Transactivates the Human Proliferating Cell Nuclear Antigen Promoter
Shivakumar, C. V., Brown, D. R., Deb, S., & Deb, S. P. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6785 · Cited by 120
A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0581 · Cited by 117
Khor, L.-Y., Bae, K., Paulus, R., Al-Saleem, T., Hammond, M. E., Grignon, D. J., Che, M., Venkatesan, V., Byhardt, R. W., Rotman, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8267 · Cited by 102
An Alternative Splice Form of Mdm2 Induces p53-independent Cell Growth and Tumorigenesis
Steinman, H. A., Burstein, E., Lengner, C., Gosselin, J., Pihan, G., Duckett, C. S., & Jones, S. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305966200 · Cited by 96
MDM2 and MDMX can interact differently with ARF and members of the p53 family
Wang, X., Arooz, T., Siu, W. Y., Chiu, C. H. S., Lau, A., Yamashita, K., & Poon, R. Y. C. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02124-x · Cited by 94
A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation
Brekman, A., Singh, K. E., Polotskaia, A., Kundu, N., & Bargonetti, J. (2011) · Breast Cancer Research · doi:10.1186/bcr2804 · Cited by 87
Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors
Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400293z · Cited by 82
Self-citationOverexpression of the MDM2 Oncogene in Leukemia and Lymphoma
Watanabe, T., Ichikawa, A., Saito, H., & Hotta, T. (1996) · Leukemia & Lymphoma · doi:10.3109/10428199609093436 · Cited by 80
Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase
Okamoto, K., Taya, Y., & Nakagama, H. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.07.021 · Cited by 76
MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation
Jackson, M. W., Lindström, M. S., & Berberich, S. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010685200 · Cited by 74
Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway
Bang, S., Kaur, S., & Kurokawa, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010261 · Cited by 69
MDMX inhibits the p300/CBP-mediated acetylation of p53
Sabbatini, P., & McCormick, F. (2002) · DNA and Cell Biology · doi:10.1089/104454902320219077 · Cited by 62
Role of poly(ADP-ribose) polymerase in cell-cycle checkpoint mechanisms following γ-irradiation
Masutani, M., Nozaki, T., Wakabayashi, K., & Sugimura, T. (1995) · Biochimie · doi:10.1016/0300-9084(96)88161-2 · Cited by 61
Analysis of glioma cell lines for amplification and overexpression of MDM2
He, J., Reifenberger, G., Liu, L., Collins, V. P., & James, C. D. (1994) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870110205 · Cited by 56
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Sriraman, A., Dickmanns, A., Najafova, Z., Johnsen, S. A., & Dobbelstein, M. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0968-0 · Cited by 40
Full-length hdmX transcripts decrease following genotoxic stress
Markey, M., & Berberich, S. J. (2008) · Oncogene · doi:10.1038/onc.2008.266 · Cited by 38
“Hdm2 (the human homologue of Mdm2) is known to bind to p53, ubiquitinating it and inhibiting its transactivation activity (Momand et al., 1992; Oliner et al., 1993; Honda et al., 1997; Fang et al., 2000).”
Reconstitution of Mdm2-dependent post-translational modifications of p53 in yeast
Di Ventura, B., Funaya, C., Antony, C., Knop, M., & Serrano, L. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001507 · Cited by 31
Noguchi, T., Oishi, S., Honda, K., Kondoh, Y., Saito, T., Kubo, T., Kaneda, M., Ohno, H., Osada, H., & Fujii, N. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.04.094 · Cited by 24
Metadata
- Authors
- Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B.
- Venue
- Nature
- Published
- 1993-04
- Volume
- 362
- Issue
- 6423
- Pages
- 857-860
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1965173366
- Cited by
- 1,451
- References
- 24
- FWCI
- 25.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.